{"id":61803,"date":"2025-09-02T10:05:27","date_gmt":"2025-09-02T08:05:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/"},"modified":"2025-09-02T10:05:27","modified_gmt":"2025-09-02T08:05:27","slug":"cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/","title":{"rendered":"CN Bio Adds Computational Modeling Capabilities to ADME Services for Enhanced Bioavailability Profiling"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>New PhysioMimix in silico tools unlock deeper functional insights from existing assays, advancing translation of MPS data to predict human ADME behavior<\/i><\/li>\n<li>\n<i>End-to-end support from experimental design to data interpretation<\/i><\/li>\n<\/ul>\n<p>CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced the expansion of its Contract Research Services (CRS) with new PhysioMimix<sup>\u00ae<\/sup> computational modeling tools. These capabilities have been developed to enhance Absorption, Distribution, Metabolism and Excretion (ADME) profiling, for accelerated drug discovery and development workflows.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20250902566866\/en\/2566839\/5\/CN_Bio_logo_for_SM.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250902566866\/en\/2566839\/22\/CN_Bio_logo_for_SM.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20250902566866\/en\/2566839\/5\/CN_Bio_logo_for_SM.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250902566866\/en\/2566839\/21\/CN_Bio_logo_for_SM.jpg\"><\/a><\/p>\n<p>\nThis launch represents the Company\u2019s new <i>in silico <\/i>tools available to customers and is designed to enhance data generation from its range of predictive <i>in vitro <\/i>tools \u2013 unlocking deeper insights into key ADME parameters, including human bioavailability, and enabling more confident <i>in vitro<\/i> to <i>in vivo<\/i> extrapolation (IVIVE).<\/p>\n<p>\nCN Bio\u2019s computational<i> <\/i>tools combine the insights gained from microphysiological system (MPS) assays with powerful mathematical models. These tools complement the Company\u2019s existing bioavailability assay based on its proprietary dual-organ Gut\/Liver model, available via the CRS or as an off-the-shelf kit. The derived data is fully compatible with physiologically-based pharmacokinetic (PBPK) frameworks and can be used to extract additional data from preclinical studies, providing functional predictions of how compounds interact with human biology.<\/p>\n<p>\nBy working with CN Bio\u2019s CRS team, customers gain access to broad support and expertise from both MPS and computational modeling specialists. The team collaborates closely with customers throughout the process, from ensuring robust study design to translating experimental data into meaningful ADME predictions. Raw data generated from projects is also translated into an easy-to-interpret format, suitable for supporting go\/no go and drug dosing decisions.<\/p>\n<p>\n<b>Dr Yassen Abbas, Lead Scientist, CN Bio, said:<\/b> <i>\u201cThis year, the FDA made significant changes to phase out animal testing requirements, signaling a clear shift towards the use of more relevant human approaches for preclinical safety and toxicity testing. We are providing the tools to ensure our customers stay ahead of these regulatory changes.\u201d <\/i><b>He added:<\/b><i> \u201cThe launch of our Bioavailability assay last year was a major step towards improving understanding of the appropriate dose regimens for safe and effective new therapies. Now, by integrating advanced in silico modeling into our offering, we are enhancing this service to bridge the in vitro to in vivo translation gap for drug developers. By working with our expert CRS team, customers have access to dedicated support throughout the entire process.\u201d<\/i><\/p>\n<p>\nFor more information on CN Bio\u2019s ADME CRS portfolio, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fcn-bio.com%2Fin-vitro-services%2Fadme%2F&amp;esheet=54316307&amp;newsitemid=20250902566866&amp;lan=en-US&amp;anchor=https%3A%2F%2Fcn-bio.com%2Fin-vitro-services%2Fadme%2F&amp;index=1&amp;md5=5d7591af94438d7afaa7c3f7e16540db\" rel=\"nofollow\" shape=\"rect\">https:\/\/cn-bio.com\/in-vitro-services\/adme\/<\/a><\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Contact<\/b><br \/>Lily Jeffery<br \/>\n<br \/>Tel: +44(0)7891 477 378<br \/>\n<br \/>Email: <a target=\"_blank\" href=\"&#109;&#97;&#x69;l&#116;&#x6f;&#x3a;l&#105;&#x6c;&#x79;&#46;&#106;&#x65;&#x66;f&#101;&#x72;&#x79;&#64;&#122;&#x79;&#x6d;e&#99;&#x6f;m&#109;&#117;&#x6e;i&#99;&#x61;&#x74;i&#111;&#x6e;&#x73;&#46;&#99;&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">lily&#46;jeffery&#64;zymecommuni&#99;&#97;&#116;&#105;&#111;&#110;&#115;&#46;&#99;&#111;&#109;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>New PhysioMimix in silico tools unlock deeper functional insights from existing assays, advancing translation of MPS data to predict human ADME behavior End-to-end support from experimental design to data interpretation CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced the expansion of &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61803","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CN Bio Adds Computational Modeling Capabilities to ADME Services for Enhanced Bioavailability Profiling - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CN Bio Adds Computational Modeling Capabilities to ADME Services for Enhanced Bioavailability Profiling - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"New PhysioMimix in silico tools unlock deeper functional insights from existing assays, advancing translation of MPS data to predict human ADME behavior End-to-end support from experimental design to data interpretation CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced the expansion of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-02T08:05:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250902566866\/en\/2566839\/22\/CN_Bio_logo_for_SM.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"CN Bio Adds Computational Modeling Capabilities to ADME Services for Enhanced Bioavailability Profiling\",\"datePublished\":\"2025-09-02T08:05:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\\\/\"},\"wordCount\":449,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250902566866\\\/en\\\/2566839\\\/22\\\/CN_Bio_logo_for_SM.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\\\/\",\"name\":\"CN Bio Adds Computational Modeling Capabilities to ADME Services for Enhanced Bioavailability Profiling - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250902566866\\\/en\\\/2566839\\\/22\\\/CN_Bio_logo_for_SM.jpg\",\"datePublished\":\"2025-09-02T08:05:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250902566866\\\/en\\\/2566839\\\/22\\\/CN_Bio_logo_for_SM.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250902566866\\\/en\\\/2566839\\\/22\\\/CN_Bio_logo_for_SM.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CN Bio Adds Computational Modeling Capabilities to ADME Services for Enhanced Bioavailability Profiling\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CN Bio Adds Computational Modeling Capabilities to ADME Services for Enhanced Bioavailability Profiling - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/","og_locale":"en_US","og_type":"article","og_title":"CN Bio Adds Computational Modeling Capabilities to ADME Services for Enhanced Bioavailability Profiling - Pharma Trend","og_description":"New PhysioMimix in silico tools unlock deeper functional insights from existing assays, advancing translation of MPS data to predict human ADME behavior End-to-end support from experimental design to data interpretation CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced the expansion of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/","og_site_name":"Pharma Trend","article_published_time":"2025-09-02T08:05:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250902566866\/en\/2566839\/22\/CN_Bio_logo_for_SM.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"CN Bio Adds Computational Modeling Capabilities to ADME Services for Enhanced Bioavailability Profiling","datePublished":"2025-09-02T08:05:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/"},"wordCount":449,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250902566866\/en\/2566839\/22\/CN_Bio_logo_for_SM.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/","url":"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/","name":"CN Bio Adds Computational Modeling Capabilities to ADME Services for Enhanced Bioavailability Profiling - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250902566866\/en\/2566839\/22\/CN_Bio_logo_for_SM.jpg","datePublished":"2025-09-02T08:05:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250902566866\/en\/2566839\/22\/CN_Bio_logo_for_SM.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250902566866\/en\/2566839\/22\/CN_Bio_logo_for_SM.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cn-bio-adds-computational-modeling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"CN Bio Adds Computational Modeling Capabilities to ADME Services for Enhanced Bioavailability Profiling"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61803"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61803\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}